MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co Inc (MRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite some short-term challenges in financial performance, the company's strong pipeline, positive analyst sentiment, and potential for long-term growth make it a solid choice.
The stock's technical indicators show mixed signals. The MACD is negative and expanding downward, indicating bearish momentum. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a positive trend. RSI is neutral at 24.147, and the stock is trading near its support level (S1: 116.08).
Analysts have consistently raised price targets, with multiple firms maintaining Buy or Overweight ratings.
Merck's strong drug pipeline, including potential best-in-class treatments like Sac-TMT, positions it well for future growth.
Positive sentiment in the news highlights Merck as a strong investment option with significant revenue growth.
Insider selling has increased significantly (2945.40% over the last month), which could indicate a lack of confidence from insiders.
Financial performance in Q4 2025 showed a decline in net income (-20.84% YoY) and EPS (-19.59% YoY), along with a drop in gross margin.
In Q4 2025, revenue increased by 4.97% YoY to $16.4 billion, but net income dropped by 20.84% YoY to $2.96 billion. EPS fell by 19.59% YoY to 1.19, and gross margin decreased by 2.78% to 74.15%.
Analysts are overwhelmingly positive on Merck, with recent upgrades and price target increases. UBS raised its target to $145, JPMorgan to $135, and Wells Fargo to $150. Analysts highlight Merck's strong pipeline and ability to navigate Keytruda's patent cliff effectively.
